About Huang Qi
Active constituents: astragalosides (notably astragaloside IV), cycloastragenol, and astragalus polysaccharides. Proposed mechanisms: immunomodulation (T-cell and macrophage activation), mild anti-inflammatory and antioxidant effects, and putative telomerase activation in vitro (cycloastragenol). Clinical evidence base is thin and largely Chinese-language: small RCTs and meta-analyses suggest possible benefit as an adjunct in chronic kidney disease (proteinuria reduction) and as an adjunct to chemotherapy (McCulloch 2006 J Clin Oncol meta-analysis of 34 trials, n=2,815, generally low-quality), but methodology is weak and results inconsistent. No high-quality Western RCTs support immune, longevity, or anti-aging claims in healthy adults. Drug interactions: may antagonize immunosuppressants (cyclosporine, tacrolimus); additive effect with antihypertensives and anticoagulants. Avoid in autoimmune disease and during immunosuppression.
What Huang Qi supports
- Traditional immune-support herb in TCM; modern evidence is preliminary and mostly low-quality
- Some signal as an adjunct in chronic kidney disease — not a standalone therapy
How much Huang Qi to take
The RDA prevents deficiency. The effective range is what clinical trials used to actually move the outcome.
Effective
200–500
mg
Standardized extract range used in most modern trials (typically standardized to astragalosides or polysaccharides). Whole-root TCM dosing is much higher (1–7 g/day decoction). Sub-200 mg of unstandardized root is below any clinically tested dose.
Clinical evidence
Limited clinical evidence. McCulloch 2006 J Clin Oncol meta-analysis (PMID 16421421) on chemotherapy adjunct use; CKD proteinuria meta-analyses with high risk of bias. No well-powered Western RCT for immune or longevity outcomes.
Reference